In this issue:
Pancreatic ductal adenocarcinoma trends from a Dutch registry
Albumin-bound paclitaxel + gemcitabine + cisplatin in advanced pancreatic cancer
Vismodegib combined with gemcitabine and nab-paclitaxel in advanced pancreatic cancer
Germline mutated pancreatic ductal adenocarcinoma platinum responder characteristics
Veliparib combined with gemcitabine and cisplatin in BRCA/PALB2 mutated pancreatic cancer
Tailoring neoadjuvant therapy in resectable oesophageal cancer patients with poor early response
Biomarker analyses in ramucirumabtreated advanced gastric cancer patients
Durvalumab +/- tremelimumab in advanced gastric and gastroesophageal junction cancer
Trifluridine/tipiracil in metastatic gastric cancer patients post-gastrectomy
Entrectinib in advanced NTRK fusion-positive solid tumours
Please login below to download this issue (PDF)